

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SOFINNOVA VENTURE PARTNERS VII, L.P.		08/26/2010	LIMITED PARTNERSHIP: DELAWARE
RECEIVING PARTY DATA			
Name:	TRIOUS THERAPEUTICS, INC.		
Street Address:	6310 Nancy Ridge Road		
Internal Address:	Suite 101		
City:	San Diego		
State/Country:	CALIFORNIA		
Postal Code:	92121		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	77150975	TRIOUS THERAPEUTICS	
Serial Number:	77150971	TRIOUS THERAPEUTICS	
CORRESPONDENCE DATA			
Fax Number:	(858)550-6420		
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>			
Phone:	858-550-6403		
Email:	erin.obrien@cooley.com		
Correspondent Name:	Erin O'Brien		
Address Line 1:	c/o Cooley LLP		
Address Line 2:	4401 Eastgate Mall		
Address Line 4:	San Diego, CALIFORNIA 92121		
ATTORNEY DOCKET NUMBER:	306814-100 IP RELEASE		
NAME OF SUBMITTER:	Erin O'Brien		

CH \$65.00 77150975

900170332

**TRADEMARK
 REEL: 004267 FRAME: 0610**

Signature:	/Erin O'Brien/
Date:	08/26/2010
Total Attachments: 6 source=Trius signed IP release#page1.tif source=Trius signed IP release#page2.tif source=Trius signed IP release#page3.tif source=Trius signed IP release#page4.tif source=Trius signed IP release#page5.tif source=Trius signed IP release#page6.tif	

RELEASE OF SECURITY INTEREST

This Release of Security Interest is made as of August ~~26~~ 2010, by SOFINNOVA VENTURE PARTNERS VII, L.P., a Delaware limited partnership, in its capacity as collateral agent ("Lender"), in favor of TRIUS THERAPEUTICS, INC., a Delaware corporation ("Company") with its principal place of business located at 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121.

Recital

WHEREAS, Company granted to Lender a security interest in the patents and trademarks described on Exhibits A and B attached hereto, respectively (collectively, the "Intellectual Property") to Lender as collateral agent for itself and for the ratable benefit of certain other parties (together with Lender, the "Lenders") under an Intellectual Property Security Agreement dated as of November 5, 2009 (the "Security Agreement"), and recorded with the US Patent and Trademark Office as set forth on Exhibits A and B.

WHEREAS, Company has no outstanding obligations to the Lenders under the terms of the Security Agreement and Lender agrees to release its security interest in the Intellectual Property.

Agreement

Now therefore, Lender, as collateral agent for itself and for the ratable benefit of the other Lenders, agrees that it terminates and releases its security interest in the Intellectual Property and reassigns to Company, without warranty or recourse, all interest of Lender in the Intellectual Property.

Lender authorizes the Company, or its agent, to terminate any financing statement on file in favor of the undersigned Lender.

LENDER:

As Collateral Agent

SOFINNOVA VENTURES PARTNERS VII, L.P.,
a Delaware limited partnership,

By: Sofinnova Management VII, L.L.C., its General Partner

By:  _____

Name: Michael Powell, Managing General Partner

140 Geary Street, 10th Floor
San Francisco, CA 94108

EXHIBIT A

Patents

Case No.	Title of Invention:	Country	Status	Application No.	Filing Date	Patent No	Date Issued	Publication Number	Publication Date
002DV1	NOVEL OXAZOLIDINONE DERIVATIVES	US	Published	12/211655	9/16/2008			2009-0192197 A1	7/30/2009
002NP	NOVEL OXAZOLIDINONE DERIVATIVES	US	Published	10/596412	6/13/2006			2007-0155798 A1	7/5/2007
002VAU	NOVEL OXAZOLIDINONE DERIVATIVES	AU	Issued	2004299413	12/17/2004	2004299413	7/9/2009		
002VBR	NOVEL OXAZOLIDINONE DERIVATIVES	BR	Published	PI0417800-9	12/17/2004				4/10/2007
002VCA	NOVEL OXAZOLIDINONE DERIVATIVES	CA	Pending	2549062	12/17/2004				
002VCN	NOVEL OXAZOLIDINONE DERIVATIVES	CN	Published	2.0048E+11	12/17/2004			CN1894242A	1/10/2007
002VEP	NOVEL OXAZOLIDINONE DERIVATIVES	EP	Published	4808458.6	12/17/2004			1699784	9/13/2006
002VIN	NOVEL OXAZOLIDINONE DERIVATIVES	IN	Pending	2167/CHENP/2006	12/17/2004				
002VJP	NOVEL OXAZOLIDINONE DERIVATIVES	JP	Pending	2006-545238	12/17/2004				
002VMX	NOVEL OXAZOLIDINONE DERIVATIVES	MX	Published	PA/a/2006/006955	12/17/2004				1/31/2007
002VNZ	NOVEL OXAZOLIDINONE DERIVATIVES	NZ	Published	547928	12/17/2004	547928	9/10/2009		5/29/2009
002VRAU	NOVEL OXAZOLIDINONE DERIVATIVES	AU	Pending	2009200606	12/17/2004				
002VRCN	NOVEL OXAZOLIDINONE DERIVATIVES	CN	Pending	4/80037612.2	12/17/2004				
002VRIN	NOVEL OXAZOLIDINONE DERIVATIVES	IN	Pending	3920/CHENP/2009	12/17/2004				
002VRU	NOVEL OXAZOLIDINONE DERIVATIVES	RU	Pending	2006125761	12/17/2004				
002VRNZ	NOVEL OXAZOLIDINONE DERIVATIVES	NZ	Pending	575842	12/17/2004				
003A	METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM	US	Pending	12/577089	10/9/2009				

Case No.	Title of Invention:	Country	Status	Application No.	Filing Date	Patent No	Date Issued	Publication Number	Publication Date
003VPC	METHODS FOR PREPARING OXAZOLIDINONES AND COMPOSITIONS CONTAINING THEM	WO	Pending	PCT/US2009/060267	40095				
004A	CRYSTALLINE FORM	US	Unfiled						
004PR	CRYSTALLINE FORM	US	Unfiled	61/149402	2/3/2009				
005A	OXAZOLIDINONE COMPOSITIONS	US	Unfiled						
005PR	OXAZOLIDINONE COMPOSITIONS	US	Pending	61/181955	5/28/2010				
1130-2	Identification and Application of Antibiotic Synergy	US	Published	11/636,379	12/8/2006			US-2007-0178111-A1	8/2/2007
1130-2JP	Identification and Application of Antibiotic Synergy	JP	Published	2008-544559	12/8/2006			2009-523120	6/18/2009
1140-1	Method for Identifying Drug-Sensitizing Antisense DNA Fragments and Use Thereof	US	Published	11/636,394	12/8/2006			US-2007-0218481-A1	9/20/2007

Lender's security interest recorded at the US Patent and Trademark Office on November 10, 2009 at Reel and Frame Number 023496/0079.

EXHIBIT B

Trademarks

TRADEMARK	COUNTRY	SERIAL No./ FILING DATE	REG. No./REG. DATE	CLASS/GOODS/SERVICES	CURRENT STATUS
<u>TRIOUS THERAPEUTICS</u>	U.S.	77/150,975 4/06/07	N/A	Class 42: Pharmaceutical research and development services; medical research and development services	Pending; Allowed
<u>TRIOUS THERAPEUTICS</u>	U.S.	77/150,971 4/06/07	N/A	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections	Pending; Allowed
TRIOUS THERAPEUTICS	Australia	1202019 10/02/07	1202019 2/18/08	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	Canada	1366205 10/03/07	N/A	Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections; Pharmaceutical research and development services; medical research and development services	Pending; Allowed <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	China (MAP)	A0009743 9/28/07	940972 11/15/07	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered [Request for Extension of Protection Filed under Madrid Protocol (Application No. <u>A0009743</u>). <i>Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i> _

TRADEMARK	COUNTRY	SERIAL NO./ FILING DATE	REG. No./REG. DATE	CLASS/GOODS/SERVICES	CURRENT STATUS
TRIOUS THERAPEUTICS	CTM	6321731 9/30/07	6321731 8/29/08	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	India	1608025 10/04/07	N/A	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Pending <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	Japan	2007-102359 10/01/07	5137735 6/06/08	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	Madrid Protocol (MAP)	A0009743 9/28/07	940972 11/15/07	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Protection claimed in China and Singapore]</i> <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>

TRADEMARK	COUNTRY	SERIAL NO./ FILING DATE	REG. No./REG. DATE	CLASS/GOODS/SERVICES	CURRENT STATUS
TRIOUS THERAPEUTICS	New Zealand	776796 10/01/07	776796 4/03/08	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975]</i>
TRIOUS THERAPEUTICS	Singapore (MAP)	T07/22072H 9/28/07	940972 9/09/08	Class 5: Anti-infective and anti-bacterial pharmaceutical preparations for the treatment of infections. Class 42: Pharmaceutical research and development services; medical research and development services	Registered <i>[Request for Extension of Protection Filed under Madrid Protocol (Application No. <u>A0009743</u>), Convention claimed as to U.S. Application Nos. 77/150,971 and 77/150,975] ..</i>

Lender's security interest recorded at the US Patent and Trademark Office on November 10, 2009 at Reel and Frame Number 004094/0180.